Logo of jnnpsycJournal of Neurology, Neurosurgery and PsychiatryVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
J Neurol Neurosurg Psychiatry. Sep 2004; 75(9): 1288–1293.
PMCID: PMC1739228

Abnormalities of cerebral perfusion in multiple sclerosis


Background: Measuring perfusion provides a potential indication of metabolic activity in brain tissue. Studies in multiple sclerosis (MS) have identified areas of decreased perfusion in grey matter (GM) and white matter (WM), but the pattern in clinical subgroups is unclear.

Objectives: This study investigated perfusion changes in differing MS clinical subgroups on or off ß-interferon therapy using a non-invasive MRI technique (continuous arterial spin labelling) to investigate whether different clinical MS subtypes displayed perfusion changes and whether this could give a further insight into the pathological mechanisms involved.

Methods: Sixty patients (21 relapsing remitting, 14 secondary progressive, 12 primary progressive, 13 benign) and 34 healthy controls were compared. Statistical parametric mapping (SPM '99) was used to investigate regional variations in perfusion in both GM and WM. Global WM perfusion was derived by segmenting WM from images using T1 relaxation times.

Results: Regions of lower perfusion in predominantly GM were observed in the primary and secondary progressive cohorts, particularly in the thalamus. Increased WM perfusion was seen in relapsing remitting and secondary progressive cohorts.

Conclusions: Low GM perfusion could reflect decreased metabolism secondary to neuronal and axonal loss or dysfunction with a predilection for progressive forms of MS. Increased WM perfusion may indicate increased metabolic activity possibly due to increased cellularity and inflammation. Improved methodology and longitudinal studies may enable further investigation of regional and temporal changes, and their relationship with physical and cognitive impairment.

Full Text

The Full Text of this article is available as a PDF (102K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Lassmann H. Neuropathology in multiple sclerosis: new concepts. Mult Scler. 1998 Jun;4(3):93–98. [PubMed]
  • Losseff NA, Wang L, Lai HM, Yoo DS, Gawne-Cain ML, McDonald WI, Miller DH, Thompson AJ. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain. 1996 Dec;119(Pt 6):2009–2019. [PubMed]
  • De Stefano Nicola, Iannucci Giuseppe, Sormani Maria P, Guidi Leonello, Bartolozzi Maria L, Comi Giancarlo, Federico Antonio, Filippi Massimo. MR correlates of cerebral atrophy in patients with multiple sclerosis. J Neurol. 2002 Aug;249(8):1072–1077. [PubMed]
  • Arnold DL, Matthews PM, Francis G, Antel J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med. 1990 Apr;14(1):154–159. [PubMed]
  • Matthews PM, Pioro E, Narayanan S, De Stefano N, Fu L, Francis G, Antel J, Wolfson C, Arnold DL. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain. 1996 Jun;119(Pt 3):715–722. [PubMed]
  • Fu L, Matthews PM, De Stefano N, Worsley KJ, Narayanan S, Francis GS, Antel JP, Wolfson C, Arnold DL. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain. 1998 Jan;121(Pt 1):103–113. [PubMed]
  • Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol. 1999 Jun;12(3):295–302. [PubMed]
  • Keir SL, Wardlaw JM. Systematic review of diffusion and perfusion imaging in acute ischemic stroke. Stroke. 2000 Nov;31(11):2723–2731. [PubMed]
  • Lojkowska Wanda, Ryglewicz Danuta, Jedrzejczak Tomasz, Sienkiewicz-Jarosz Halina, Minc Slawomira, Jakubowska Teresa, Kozlowicz-Gudzinska Izabela. SPECT as a diagnostic test in the investigation of dementia. J Neurol Sci. 2002 Nov 15;203-204:215–219. [PubMed]
  • Varrone Andrea, Pappatà Sabina, Caracò Corradina, Soricelli Andrea, Milan Graziella, Quarantelli Mario, Alfano Bruno, Postiglione Alfredo, Salvatore Marco. Voxel-based comparison of rCBF SPET images in frontotemporal dementia and Alzheimer's disease highlights the involvement of different cortical networks. Eur J Nucl Med Mol Imaging. 2002 Nov;29(11):1447–1454. [PubMed]
  • Pasquier Jacques, Michel Bernard F, Brenot-Rossi Isabelle, Hassan-Sebbag Nathalie, Sauvan Richard, Gastaut Jean Louis. Value of (99m)Tc-ECD SPET for the diagnosis of dementia with Lewy bodies. Eur J Nucl Med Mol Imaging. 2002 Oct;29(10):1342–1348. [PubMed]
  • Brooks DJ, Leenders KL, Head G, Marshall J, Legg NJ, Jones T. Studies on regional cerebral oxygen utilisation and cognitive function in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1984 Nov;47(11):1182–1191. [PMC free article] [PubMed]
  • Lycke J, Wikkelsö C, Bergh AC, Jacobsson L, Andersen O. Regional cerebral blood flow in multiple sclerosis measured by single photon emission tomography with technetium-99m hexamethylpropyleneamine oxime. Eur Neurol. 1993;33(2):163–167. [PubMed]
  • Pozzilli C, Passafiume D, Bernardi S, Pantano P, Incoccia C, Bastianello S, Bozzao L, Lenzi GL, Fieschi C. SPECT, MRI and cognitive functions in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1991 Feb;54(2):110–115. [PMC free article] [PubMed]
  • Parkes Laura M, Tofts Paul S. Improved accuracy of human cerebral blood perfusion measurements using arterial spin labeling: accounting for capillary water permeability. Magn Reson Med. 2002 Jul;48(1):27–41. [PubMed]
  • Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996 Apr;46(4):907–911. [PubMed]
  • Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 Mar;13(3):227–231. [PubMed]
  • Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444–1452. [PubMed]
  • Alsop DC, Detre JA. Reduced transit-time sensitivity in noninvasive magnetic resonance imaging of human cerebral blood flow. J Cereb Blood Flow Metab. 1996 Nov;16(6):1236–1249. [PubMed]
  • Steen RG, Gronemeyer SA, Kingsley PB, Reddick WE, Langston JS, Taylor JS. Precise and accurate measurement of proton T1 in human brain in vivo: validation and preliminary clinical application. J Magn Reson Imaging. 1994 Sep-Oct;4(5):681–691. [PubMed]
  • Vymazal J, Righini A, Brooks RA, Canesi M, Mariani C, Leonardi M, Pezzoli G. T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. Radiology. 1999 May;211(2):489–495. [PubMed]
  • Miller DH, Johnson G, Tofts PS, MacManus D, McDonald WI. Precise relaxation time measurements of normal-appearing white matter in inflammatory central nervous system disease. Magn Reson Med. 1989 Sep;11(3):331–336. [PubMed]
  • Filippi M, Gawne-Cain ML, Gasperini C, vanWaesberghe JH, Grimaud J, Barkhof F, Sormani MP, Miller DH. Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis. Neurology. 1998 Jan;50(1):238–244. [PubMed]
  • Leenders KL, Perani D, Lammertsma AA, Heather JD, Buckingham P, Healy MJ, Gibbs JM, Wise RJ, Hatazawa J, Herold S, et al. Cerebral blood flow, blood volume and oxygen utilization. Normal values and effect of age. Brain. 1990 Feb;113(Pt 1):27–47. [PubMed]
  • Haselhorst R, Kappos L, Bilecen D, Scheffler K, Möri D, Radü EW, Seelig J. Dynamic susceptibility contrast MR imaging of plaque development in multiple sclerosis: application of an extended blood-brain barrier leakage correction. J Magn Reson Imaging. 2000 May;11(5):495–505. [PubMed]
  • Brück W, Lucchinetti C, Lassmann H. The pathology of primary progressive multiple sclerosis. Mult Scler. 2002 Apr;8(2):93–97. [PubMed]
  • Cifelli Alberto, Arridge Marzena, Jezzard Peter, Esiri Margaret M, Palace Jacqueline, Matthews Paul M. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol. 2002 Nov;52(5):650–653. [PubMed]
  • Blinkenberg M, Rune K, Jensen CV, Ravnborg M, Kyllingsbaek S, Holm S, Paulson OB, Sørensen PS. Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS. Neurology. 2000 Feb 8;54(3):558–564. [PubMed]
  • Paulesu E, Perani D, Fazio F, Comi G, Pozzilli C, Martinelli V, Filippi M, Bettinardi V, Sirabian G, Passafiume D, et al. Functional basis of memory impairment in multiple sclerosis: a[18F]FDG PET study. Neuroimage. 1996 Oct;4(2):87–96. [PubMed]
  • Allen IV, Glover G, Anderson R. Abnormalities in the macroscopically normal white matter in cases of mild or spinal multiple sclerosis (MS). Acta Neuropathol Suppl. 1981;7:176–178. [PubMed]
  • Debruyne JC, Versijpt J, Van Laere KJ, De Vos F, Keppens J, Strijckmans K, Achten E, Slegers G, Dierckx RA, Korf J, et al. PET visualization of microglia in multiple sclerosis patients using [11C]PK11195. Eur J Neurol. 2003 May;10(3):257–264. [PubMed]
  • Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F, Price G, Wegner F, Giovannoni G, Miller DH, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain. 2000 Nov;123(Pt 11):2321–2337. [PubMed]
  • Sellebjerg F, Jensen CV, Larsson HBW, Frederiksen JL. Gadolinium-enhanced magnetic resonance imaging predicts response to methylprednisolone in multiple sclerosis. Mult Scler. 2003 Feb;9(1):102–107. [PubMed]
  • Thompson AJ, Kermode AG, Wicks D, MacManus DG, Kendall BE, Kingsley DP, McDonald WI. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol. 1991 Jan;29(1):53–62. [PubMed]
  • Thompson AJ, Miller D, Youl B, MacManus D, Moore S, Kingsley D, Kendall B, Feinstein A, McDonald WI. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology. 1992 Jan;42(1):60–63. [PubMed]
  • Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol. 1999 Aug;46(2):197–206. [PubMed]
  • Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998 Jan 29;338(5):278–285. [PubMed]
  • Evangelou N, Esiri MM, Smith S, Palace J, Matthews PM. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol. 2000 Mar;47(3):391–395. [PubMed]
  • Detre JA, Leigh JS, Williams DS, Koretsky AP. Perfusion imaging. Magn Reson Med. 1992 Jan;23(1):37–45. [PubMed]
  • Tofts PS, Kermode AG. Blood brain barrier permeability in multiple sclerosis using labelled DTPA with PET, CT and MRI. J Neurol Neurosurg Psychiatry. 1989 Aug;52(8):1019–1020. [PMC free article] [PubMed]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Group


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...